Moderna’s COVID-19 vaccine has received full FDA approval for use in children at higher risk for severe illness.

The company expects to make the updated Spikevax available to U.S. patients in time for the 2025-26 respiratory virus season.

Vinay Prasad overruled other reviewers for a third time in recent months in clearing only narrow use of Moderna's vaccine in ...

In a July 9 memo, the director of the FDA's Center for Biologics Evaluation and Research contended there was not enough ...

Cambridge: Moderna has received approval from the U.S. Food and Drug Administration (FDA) for the supplemental Biologics ...

FDA accepts GSK's filing to extend Arexvy's RSV vaccine use to high-risk adults under 50, with a decision due in 2026.

State Surgeon General Dr. Joseph Ladapo is speaking to the community about the updated federal recommendations for healthy ...

CSIR-Centre for Cellular and Molecular Biology (CCMB) Atal Incubation Centre (AIC) is planning to go ahead with the next stage larger-scale trials of the indigenously developed mRNA vaccine technology ...

The label expansion sought by GSK is a bid to compete with Pfizer and Moderna in the younger age groups of the RSV vaccine market. Pfizer’s Abrysvo and Moderna’s mRESVIA are both approved to prevent ...

Seven biotech unicorns are advancing AI-powered drug discovery and development—but must contend with a difficult investing ...

It's difficult to get motivated about buying a stock that's plummeted or a company that seems to be out of favor with the ...

As vaccination rates among children continue to plummet, concerns are rising over the potential for infectious disease to spread rampantly.